Hints and tips:
Showing results for Noven Pharmaceuticals Inc. v. Mylan Technologies Inc.
...In the June letter to Gilead, MSF and its co-authors accused the company of long hiding the technology that underpins the manufacture of the drug as a “trade secret”, preventing the creation of a stable...
...Mainz-based BioNTech, whose vaccine relies on mRNA technology, stressed that the speeded-up process by the EMA would not dilute the regulator’s safety standards....
...According to Morgan Stanley Wealth Management, the sectors that have benefited the most from low taxes and the use of offshore locations are technology and pharmaceuticals — two of the stronger recent performers...
...Beyond these three biotechs, Crispr could end up transforming the entire pharmaceutical industry....
...Mylan does not make the EpiPens itself. It gave the job to Pfizer, the US pharmaceutical company, which it seems messed it up....
...Fujifilm has teamed up with a Japanese pharma company, Kyowa Hakko Kirin Biologics, and said that, by merging technologies developed through its photographic film business with Kyowa’s expertise in biopharma...
...Pharmaceutical groups, which might see similar benefits from quantum technology in the long term, are still on the sidelines....
...Thanks to a series of court rulings since the mid-2000s, such as eBay v MercExchange in 2007, Mayo Collaborative Services v Prometheus Laboratories in 2012 and Alice Corp v CLS Bank in 2014, and the subsequent...
...If successful, the ploy would close down one route used by generic drugmakers, such as Teva Pharmaceuticals, Mylan and Akorn, which are trying to have Allergan’s intellectual property invalidated so they...
...Another alternative would focus on the use of intellectual property in tax avoidance — common in the technology and pharmaceuticals sectors — by imposing a tax on foreign income derived from IP....
...Abbott’s acquisition may also spark a fresh wave of healthcare M&A, with a focus on the technology-focused medical devices sector....
...● Related Lex note: Asahi Group — sinking pints Mylan’s takeover of Meda turns into bad medicine for stock Mylan, the Netherlands-based drugmaker, agreed to take over Meda of Sweden for $9.9bn including...
...New York-listed shares of Israeli drugmaker Teva Pharmaceuticals rose more than 1 per cent to $64.16, after the company offered to buy US drugmaker Mylan....
...Look out for Skynet 3D Printing Inc’s crowdfunding campaign to build a time machine very soon. Back to the top of the page...
...Aberdeen Asset Management and Canada Pension Plan have also voiced opposition to the deal, as has the local company Ilsung Pharmaceuticals, which holds 2 per cent....
...Mylan climbed after the Pennsylvania-based pharmaceutical company lifted its third-quarter guidance on recent product approvals and launches....
...Nine other companies doing inversions do not disclose their offshore cash while Mylan holds just $174m outside the US....
...The companies are to pay 7 per cent of their revenues as royalty to Gilead, which will provide full technology transfer to the Indian manufacturers, allowing them to produce both the active pharmaceutical...
...The pharmaceutical industry sustained this year’s frenetic pace of dealmaking on Monday, when US drugmaker Mylan agreed to buy a series of medicines from rival Abbott for $5.3bn in shares....
...Mylan’s pursuit of Sweden’s Meda, Mallinckrodt’s merger with Questcor and Fyffes’ tie up with rival banana seller Chiquita are all motivated, in part at least, by tax....
...Epizyme, Agios Pharmaceuticals, Zogenix and Novavax all fell by more than a tenth as nine in ten stocks in the index fell. Larger companies, including Gilead, Mylan, and Grifols also slid....
...(Financial Times) Roche is to buy Santaris Pharma for up to $450m in the latest piece of dealmaking by the Swiss pharmaceuticals group....
...It has since agreed to retain 650 posts and negotiated a deal with Mylan, a US generics company, to tap staff and operate on the site....
...He has consulted frequently on both pharmaceutical and high tech issues....
...Shares in Teva Pharmaceutical, which was also mentioned as a potential bidder for Merck’s generic unit but was beaten to the punch by Mylan, moved a touch higher at $39.98....
International Edition